½ÃÀ庸°í¼­
»óǰÄÚµå
1665292

Æä¼­¸® ½ÃÀå : ½ÃÀå ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м®, ¿¹Ãø(2025-2034³â)

Pessary Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 130 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Æä¼­¸® ½ÃÀåÀº 2024³â¿¡ 4¾ï 4,750¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2025³âºÎÅÍ 2034³â±îÁö CAGR 4.8%·Î ¾ÈÁ¤µÈ ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ÀÌ ¼ºÀåÀº ÁÖ·Î °ñ¹ÝÀå±âÅ»(POP)°ú ¿ä½Ç±Ý À¯º´·ü Áõ°¡, ½Ã±âÀûÀýÇÑ Áø´Ü°ú Ä¡·áÀÇ Á߿伺¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡, ºñħ½ÀÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡, ¿©¼ºÀÇ °Ç°­ ÇÁ·Î±×·¥À» Áö¿øÇÏ´Â Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºêÀÇ °­È­¿¡ ÀÇÇØ ÃÊ·¡µË´Ï´Ù.

Pessary Market-IMG1

½ÃÀåÀº À¯Çüº°·Î ±¸ºÐµÇ¸ç, ¸µ Æä¼­¸®´Â 2024³â ½ÃÀå Á¡À¯À²ÀÇ 51.6%¸¦ Â÷ÁöÇÏ¿© ¼±µµÇß½À´Ï´Ù. ¸µ Æä¼­¸®°¡ ¿ìÀ§¸¦ À¯ÁöÇϰí ÀÖ´Â ÀÌÀ¯´Â ¹ü¿ë¼º, »ç¿ëÀÇ ¿ëÀ̼º, °æ·®ÀÇ ÄèÀû¼º¿¡ ÀÖ¾î, °æµµ·ÎºÎÅÍ ÁߵÀÇ Å»Ç×À̳ª ½ºÆ®·¹½º¼º ¿ä½Ç±Ý¿¡ °í¹ÎÇÏ´Â »ç¶÷¿¡°Ô ÃÖÀûÀÔ´Ï´Ù. ±× µðÀÚÀÎÀº ÀÚ±ØÀ» ÁÙÀ̰í Àå½Ã°£ »ç¿ëÀ» °¡´ÉÇÏ°Ô Çϱâ À§ÇØ ÀÓ»ó ÇöÀå¿¡¼­ ¼±È£µÇ°í ³Î¸® ¹Þ¾Æµé¿©Áö´Â ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¹üÀ§
½ÃÀÛ ¿¬µµ 2024³â
¿¹Ãø ¿¬µµ 2025-2034³â
½ÃÀÛ ±Ý¾× 4¾ï 4,750¸¸ ´Þ·¯
¿¹Ãø ±Ý¾× 7¾ï 1,180¸¸ ´Þ·¯
CAGR 4.8%

ÃÖÁ¾ »ç¿ëÀÚº°·Î º´¿øÀº ÁÖ¿ä ºÎ¹®À¸·Î ºÎ»óÇÏ¿© 2024³â ½ÃÀå Á¡À¯À²ÀÇ 46.2%¸¦ Â÷ÁöÇß½À´Ï´Ù. º´¿øÀº POP ¹× ½ºÆ®·¹½º¼º ¿ä½Ç±Ý°ú °°Àº °ñ¹ÝÀúÀå¾ÖÀÇ Áø´Ü, °ü¸®, Ä¡·á¿¡ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ÀÌ ÀÇ·á ±â°üÀº ¼ö¼úÀû ¹× ºñ ¼ö¼úÀû Æä¼­¸® Ä¡·á¸¦ ¸ðµÎ Á¦°øÇÏ¸ç ´Ù¾çÇÑ ÁßÁõµµÀÇ È¯ÀÚ¸¦ ¼ö¿ëÇÕ´Ï´Ù. º¹ÀâÇÑ »ç·Ê¿¡ ´ëÀÀÇϰí ÇʼöÀûÀÎ ÈÄ¼Ó °ü¸®¸¦ Á¦°øÇÏ´Â ´É·ÂÀº Æä¼­¸® ½ÃÀå¿¡¼­ ¿ìÀ§¸¦ ´õ¿í °­È­Çϰí ÀÖ½À´Ï´Ù.

¹Ì±¹ÀÇ Æä¼­¸® ½ÃÀåÀº 2024³â¿¡ 1¾ï 6,970¸¸ ´Þ·¯·Î Æò°¡µÇ¾úÀ¸¸ç, ¿©ÀüÈ÷ °­·ÂÇÑ ¼ºÀå °¡´É¼ºÀ» º¸¿©ÁÝ´Ï´Ù. ºñ¸¸°ú °°Àº »ýȰ½À°ü°ú °ü·ÃµÈ °Ç°­»óÅÂ¿Í ÇÔ²² °ñ¹ÝÀå¾Ö Áõ°¡´Â È¿°úÀûÀÌ°í ºñħ½ÀÀûÀÎ Ä¡·á ¼Ö·ç¼ÇÀ¸·Î¼­ Æä¼­¸® ¼ö¿ä Áõ°¡¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á¿¡ ´ëÇÑ Á¢±ÙÀÌ È®´ëµÇ°í °ñ¹ÝÀÇ °Ç°­ ¹®Á¦¿¡ ´ëÇÑ ÀǽÄÀ» ³ôÀÌ´Â ³ë·ÂÀÌ °è¼ÓµÇ°í ÀÖ´Â °ÍÀÌ, ±¹³» Àü¿ª¿¡¼­ ½ÃÀåÀÇ Áö¼ÓÀûÀÎ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý ¹× Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå »ê¾÷ ÀλçÀÌÆ®

  • »ýÅÂ°è ºÐ¼®
  • »ê¾÷¿¡ ¹ÌÄ¡´Â ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • °ñ¹ÝÀå±â Å» ¹× ¿ä½Ç±ÝÀÇ À¯º´·ü Áõ°¡
      • Àû½ÃÀÇ Áø´Ü ¹× Ä¡·á¿¡ ´ëÇÑ ÀǽÄÀÇ °íÁ¶
      • ºñħ½ÀÀû Ä¡·á ¿É¼ÇÀÇ Ã¤¿ë Áõ°¡
      • ¿©¼º °Ç°­ ÇÁ·Î±×·¥¿¡ À־ Á¤ºÎ Áö¿ø Áõ°¡
    • »ê¾÷ÀÇ ÀáÀçÀû ¸®½ºÅ© ¹× °úÁ¦
      • »çȸÀû ½ºÆ¼±×¸¶¿Í ½É¸®Àû À庮
      • Àå±â »ç¿ëÀ¸·Î ÀÎÇÑ °¨¿° À§Çè¿¡ ´ëÇÑ ¿ì·Á
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • ƯÇ㠺м®
  • °¸ ºÐ¼®
  • ±ÔÁ¦ »óȲ
  • ±â¼úÀû Àü¸Á
  • ÇâÈÄ ½ÃÀå µ¿Çâ
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼­¹®
  • ±â¾÷ Á¡À¯À² ºÐ¼®
  • ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷ÀÇ °æÀï ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« Àü¸Á

Á¦5Àå ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø : À¯Çüº°(2021-2034³â)

  • ÁÖ¿ä µ¿Çâ
  • ¸µ
  • µµ³Ó
  • °ÖÈ¥
  • ±âŸ

Á¦6Àå ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø : ¿ëµµº°(2021-2034³â)

  • ÁÖ¿ä µ¿Çâ
  • °æµµÀÇ °ñ¹Ý Àå±â Å»
  • ½ºÆ®·¹½º¼º ¿ä½Ç±Ý
  • ½ÉÇÑ °ñ¹ÝÀå±â Å»
  • ±âŸ

Á¦7Àå ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø : ÃÖÁ¾ ¿ëµµº°(2021-2034³â)

  • ÁÖ¿ä µ¿Çâ
  • º´¿ø
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • Ŭ¸®´Ð
  • ±âŸ

Á¦8Àå ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø : Áö¿ªº°(2021-2034³â)

  • ÁÖ¿ä µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)

Á¦9Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • Artisan Medical
  • BIoTeque America
  • Bliss GVS Pharma
  • Bray Group(Ethos Partners)
  • Coloplast Group
  • Contiform International
  • CooperSurgical
  • Dr. Arabin
  • Integra Lifesciences
  • MedGyn Products
  • Novomed group(Gyneas)
  • Panpac Medical
  • Personal Medical
  • Smiths Group
  • Sugar International
AJY 25.03.27

The Global Pessary Market was valued at USD 447.5 million in 2024 and is projected to experience steady growth at a CAGR of 4.8% from 2025 to 2034. This growth is primarily driven by the increasing prevalence of pelvic organ prolapse (POP) and urinary incontinence, heightened awareness about the importance of timely diagnosis and treatment, growing preference for non-invasive therapy options, and strengthened government initiatives supporting women's health programs.

Pessary Market - IMG1

The market is segmented by type, with the ring pessary leading the way, accounting for 51.6% of the market share in 2024. The ring pessary's continued dominance can be attributed to its versatility, ease of use, and lightweight comfort, making it ideal for individuals suffering from mild to moderate prolapse and stress urinary incontinence. Its design reduces irritation and allows for prolonged use, making it a favored choice in clinical settings and contributing to its widespread acceptance.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$447.5 Million
Forecast Value$711.8 Million
CAGR4.8%

By end user, hospitals emerged as the leading segment, capturing 46.2% of the market share in 2024. Hospitals play a pivotal role in diagnosing, managing, and treating pelvic floor disorders such as POP and stress urinary incontinence. These institutions offer both surgical and non-surgical pessary treatments, catering to patients with varying levels of severity. Their ability to handle complex cases and provide essential follow-up care further reinforces their dominance in the pessary market.

In the United States, the pessary market was valued at USD 169.7 million in 2024 and continues to show strong growth potential. The rise in pelvic disorders, alongside lifestyle-related health conditions like obesity, is driving the increasing demand for pessaries as effective, non-invasive treatment solutions. The expansion of healthcare access and ongoing efforts to raise awareness about pelvic health issues are contributing to the continued market growth across the country.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of pelvic organ prolapse and urinary incontinence
      • 3.2.1.2 Growing awareness towards timely diagnosis and treatment
      • 3.2.1.3 Increasing adoption of non-invasive treatment options
      • 3.2.1.4 Growing government support in women health programs
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Social stigma and psychological barrier
      • 3.2.2.2 Concerns related to risk of infections due to prolonged use
  • 3.3 Growth potential analysis
  • 3.4 Patent analysis
  • 3.5 Gap analysis
  • 3.6 Regulatory landscape
  • 3.7 Technological landscape
  • 3.8 Future market trends
  • 3.9 Porter’s analysis
  • 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy outlook

Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Ring
  • 5.3 Donut
  • 5.4 Gellhorn
  • 5.5 Other types

Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Mild pelvic organ prolapse
  • 6.3 Stress urinary incontinence
  • 6.4 Severe pelvic organ prolapse
  • 6.5 Other applications

Chapter 7 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Ambulatory surgical centers
  • 7.4 Clinics
  • 7.5 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE

Chapter 9 Company Profiles

  • 9.1 Artisan Medical
  • 9.2 Bioteque America
  • 9.3 Bliss GVS Pharma
  • 9.4 Bray Group (Ethos Partners)
  • 9.5 Coloplast Group
  • 9.6 Contiform International
  • 9.7 CooperSurgical
  • 9.8 Dr. Arabin
  • 9.9 Integra Lifesciences
  • 9.10 MedGyn Products
  • 9.11 Novomed group (Gyneas)
  • 9.12 Panpac Medical
  • 9.13 Personal Medical
  • 9.14 Smiths Group
  • 9.15 Sugar International
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦